PsaeA.17981.a
Proline--tRNA ligase (EC 6.1.1.15) (Prolyl-tRNA synthetase) (ProRS)
CENTER ID:
PsaeA.17981.a
ORGANISM:
Pseudomonas aeruginosa PAO1
ASSOCIATED DISEASE:
Pseudomonas infection
CURRENT STATUS:
in PDB
COMMUNITY REQUEST:
True
NIH RISK GROUP:
unclassified
SELECT AGENT:
False
NIH PRIORITY
pathogens category:
unclassified
Ordering Clones & Proteins
If there are materials available for this target, they will be listed below.
Materials can be ordered from SSGCID using the button in the "order material" column.
Clicking the button will add the material to a virtual cart.
You may order multiple materials at a time at no cost to you, as this contract is funded
by NIAID. When you are ready to place your order, click the "Place Order" link which will
appear in the top right corner of the page after you place your first item in your cart.
Clones*
CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO
AA
START
AA
STOP
ORDER
MATERIAL
PsaeA.17981.a.B1.GE38513
full length
info
1
571
PsaeA.17981.a.B1.GE38513
* SSGCID clones represent un-induced expression constructs which have been verified by sequencing from vector primers. Clones may contain a tag, such as N-term 6xHis . Get sequence information
using the button in the "info" column.
Proteins
CENTER REFERENCE ID
DOMAIN/REGION DESCRIPTION
INFO
AA START
AA STOP
ORDER MATERIAL
PsaeA.17981.a.B1.PW37621
full length
info
1
571
PW37621
Structures
5UCM
DEPOSITED: 12/22/2016
DETERMINATION: XRay
CLONE: PsaeA.17981.a.B1.GE38513
PROTEIN: PsaeA.17981.a.B1.PW37621
Publications by SSGCID
Characterization and structure determination of prolyl-tRNA synthetase from Pseudomonas aeruginosa and development as a screening platform
Dranow DM, Bullard JM, Pena N, Hu Y, Escamilla Y
Protein Sci. - 2019
Sequences
These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols.
To find the specific sequence of any material you may have ordered, click on the "info" button next to the name of that material.
AA Sequence
MRTSQYLLST LKETPADAVV ISHQLLLRAG MIRRLASGLY TWLPMGLRVL RKVETIVREE MNAAGALEVL MPAVQPAELW QESGRWEQYG PELLRLKDRH EREFCVGPTH EEVITDLARN ELNSYKQLPI NFYQIQTKFR DEIRPRFGLM RGREFIMKDA YSFHLSQDSL QQTYDGMYQA YSKIFSRLGL DFRPVQADNG SIGGSGSHEF HVLANSGEDD IVFSDSSDYA ANIEKAEAVP RESARGSATE DMRLVDTPNT KTIAALVDGF QLPIEKTIKT LVVHGAEEGT LVALIVRGDH ELNEIKAANQ PLVASPLVFA SEAEIRAAIG AGPGSLGPVN LPIACIVDRS VALMSDFAAG ANIEDKHYFG VNWERDLPLP EVADLRNVVE GDPSPDGKGT LVIKRGIEVG HIFQLGTKYS EAMKLSVLSE QGKPVNLIMG CYGIGVSRVV AAAIEQNHDE RGILWPSALA PFQIALVPLK YETESVKQAT DKLYAELTAA GFEVLLDDRD KKTSPGVKFA DMELIGIPHR IVISDRGLSE GVLEYKGRRD SESQNLPIGE LMSFITEKLS R
NT Sequence
atgcgtacca gtcagtatct gctttccacg ctcaaagaaa cccccgccga cgcggtggta atcagccatc aactgctgct tcgcgccggc atgatccgtc gcctggcctc gggtctctac acctggctgc caatgggcct gcgggtactg cgcaaggtcg agaccatcgt ccgcgaggaa atgaacgctg ccggcgccct ggaagtgctg atgccggcgg tgcagccggc cgagctgtgg caggagtcgg ggcgctggga gcaatacggc cctgagctgc tgcgcctgaa ggaccgccac gagcgcgaat tctgcgtagg cccgacccac gaagaagtga tcaccgacct cgcgcgcaac gagctgaaca gctacaagca actgccgatc aacttctatc agatccagac caagttccgc gatgagatcc gcccgcgctt cggcctgatg cgcggacgcg aattcatcat gaaggacgcc tattccttcc acctgagcca ggactcgctg cagcagacct acgacgggat gtaccaggcg tacagcaaga tcttctcccg cctcggcctg gatttccgtc ccgtgcaagc cgacaacggc tccatcggcg gcagcggctc ccatgagttc cacgtgctgg ccaactccgg cgaggacgat atcgtcttca gcgacagctc cgactacgcc gcgaacatcg agaaggccga agccgtgccg cgcgagagcg cccgcggcag cgccaccgag gacatgcgcc tggtcgacac gcccaacacc aagaccatcg cggccctggt ggacggcttc cagctaccga tcgagaaaac catcaagacc ctggtggtgc atggcgccga agaaggcacc ctggtcgccc tgatcgtccg cggtgatcac gagctcaacg aaatcaaggc cgccaaccag ccgctggtcg ccagcccgct ggtattcgct tcggaggccg agatccgtgc cgccatcggt gccggccccg gctcgctggg cccggtcaac ctgccgatcg cctgcatcgt cgaccgctcc gtcgccctga tgagcgattt cgccgctggc gccaacatcg aggacaagca ctacttcggc gtgaactggg agcgcgacct gccgctgccc gaggtcgccg acctgcgcaa tgtcgtcgaa ggcgacccca gcccggacgg caagggcacc ctggtgatca agcgcggcat cgaggtcggt catatcttcc agcttggcac caagtacagc gaagcgatga agctgagcgt cctgagcgaa cagggcaagc cggtcaacct gatcatgggc tgctacggca tcggcgtatc ccgcgtggtc gccgccgcca tcgagcagaa ccatgacgag cgcggcattc tctggccaag cgcattggcg ccgttccaga tcgccctggt accgctgaag tacgaaaccg agagcgtcaa gcaggcgacc gacaagctct atgccgagct gaccgcagcc ggtttcgaag tgctgctgga cgatcgcgac aagaagacca gccccggggt gaagttcgcc gacatggagc tgatcggcat tccccaccgc atcgtgatca gcgaccgcgg cctcagcgaa ggcgtcctgg aatacaaggg ccgccgcgac agcgagtcgc agaacctgcc gatcggcgaa ctgatgtcgt tcatcaccga aaaactcagc cgctga
Details for PsaeA.17981.a.B1.GE38513
HARVESTED ON:
10/9/2014
SEQUENCED ON:
11/24/2014
EXPECTED MW:
64kDa
OBSERVED MW:
64kDa
ANTIBIOTIC MARKER:
ampicillin
COUNT OF EXPRESSION COLONIES:
Too many to count (100+)
TOTAL EXPRESSION LEVEL:
High Expression
SOLUBLE EXPRESSION LEVEL
High Expression
EXPRESSION HOST:
data unavailable
SEQUENCING RESULT:
PERCENT IDENTITY:
100
PERCENT COVERAGE:
100
Details for PsaeA.17981.a.B1.PW37621
PURIFICATION DATe:
1/5/2015
CONCENTRATION:
9.5mg/ml
OBSERVED MW:
64kDa
EXPRESSION LEVEL:
Moderate Expression
PROTEIN PURIFICATION BUFFER:
25 mM HEPES pH 7.0, 500 mM NaCl, 5% Glycerol , 2 mM DTT, and 0.025% Azide
EXPRESSION HOST:
data unavailable
VIAL COUNT (approx.):
1
VIAL VOLUME:
110µl
PERCENT IDENTITY:
100
PERCENT COVERAGE:
100